HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.
HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.
Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.
Administering a 2-part prime-boost vaccine prevented infection in half of a dozen rhesus monkeys repeatedly exposed to simian immunodeficiency virus (SIV), and antibody responses against viral envelope proteins appeared to be the key to protection, according to a study published in the July 2 advance edition of Science magazine.
HIV-positive people who inject drugs and those who are coinfected with hepatitis C virus (HCV) have elevated mortality rates, according to a report from the ART Cohort Collaboration published in the July 1 Journal of Acquired Immune Deficiency Syndromes. HIV/HCV coinfected drug injectors had a high risk of liver-related death, but those without HCV still had higher mortality due to various causes compared with non-injectors.